Risk Factors Identified for Hypertension, Proteinuria Due to VSPIs for Cancer – Renal and Urology News
Hypomagnesemia was one of several risk factors identified for high-grade hypertension after VSPI initiation for cancer treatment.
Hypomagnesemia was one of several risk factors identified for high-grade hypertension after VSPI initiation for cancer treatment.
INTRODUCTION AND OBJECTIVE:Symptoms of overactive bladder (OAB) may persist in men being treated for benign prostatic hyperplasia (BPH). Vibegron is a selective β3 agonist being…
The AUA invites the global urologic community to the 119th AUA Annual Meeting in the dynamic city of San Antonio, TX!
INTRODUCTION AND OBJECTIVE:The use of AI-powered chatbots is increasingly finding application in healthcare. AI-based chatbots can act as automated conversational agents, capable of promoting health…
Friday, May 3, 2024 3:15 PM to 3:45 PM · 30 min. (US/Central)
Treatment with the intravesical gemcitabine delivery system TAR-200 led to complete responses in over 80% of patients with BCG-unresponsive, high-risk non–muscle-invasive bladder cancer, according to…
Topic: Spatial Biology in Benign and Malignant Urologic Disease Symposium Goal: Benign and malignant prostate diseases display high cellular heterogeneity. While single cell assays provide…
A phase 3 trial demonstrates a high rate of complete response with cretostimogene, an investigational immunotherapy administered intravesically.
Can’t sign in? Forgot your password? If the address matches an existing account you will receive an email with instructions to reset your password. Can’t…
Compared with oncologists, urologists report more barriers to using standard of care treatment intensification in the first-line setting for metastatic
AUA 2024 advanced prostate cancer, molecular imaging (mi) node positive disease (miN1) undergoing radical prostatectomy, extended pelvic lymph node dissection (ePLND).